- £40.62m
- £41.55m
- £46.77m
Director/PDMR Shareholding
Brief: hVIVO To Conduct Phase Iii Human Challenge Whooping Cough Vaccine Trial For ILiAD Biotechnologies
HCT contract signed with ILiAD Biotechnologies
Brief: hVIVO Says Board Decides Not To Pay Nominal Dividend For 2025
Final Results 2025
hVIVO launches unified brand identity
Influenza HCT contract signed with Traws Pharma
Notice of Results
Holding(s) in Company
Holding(s) in Company
Holding(s) in Company
Holding(s) in Company
Brief: hVIVO Reiterates Guidance For High Single Digit Revenue Growth In 2026
Trading Update
Appointment of Non-Executive Director
CEO & CFO Share Purchase
MSD to acquire Cidara
>£5 million CRS contracts signed
Positive data from novel human challenge models